Dexamethasone improved disability in acute bacterial meningitis


**QUESTION:** In patients with acute bacterial meningitis, does adjunctive treatment with dexamethasone improve outcomes more than placebo?

**Design**
Randomised (allocation concealed*), blinded (clinicians, patients, data collectors, outcome assessors, data analysts, data monitoring committee, and manuscript writers)*, *placebo controlled trial with 8 weeks of follow up.

**Setting**
52 centres in the Netherlands, Belgium, Germany, Denmark, and Austria.

**Patients**
301 patients (mean age 45 y, 56% men) who had suspected meningitis in combination with cloudy cerebrospinal fluid, bacteria in cerebrospinal fluid on Gram staining, or cerebrospinal fluid leukocyte count > 1000/μm³. Exclusion criteria included hypersensitivity to β-lactam antibiotics or corticosteroids; cerebrospinal shunt; antibiotics in the past 48 hours; and history of active tuberculosis or fungal infection, head trauma, neurosurgery, or peptic ulcer disease. All patients were included in the analysis.

**Intervention**
Patients were allocated to intravenous dexamethasone, 10 mg every 6 hours for 4 days (n = 157), or placebo (n = 144). All patients received parenteral antibiotics.

**Main outcome measures**
The primary outcome was score on the Glasgow Outcome Scale (score of 5=favourable outcome [mild or no disability], and 1–4=unfavourable outcome [range, death to moderate disability]). Secondary outcomes were death, focal neurological abnormalities, hearing loss, gastrointestinal bleeding, fungal infection, herpes zoster, and hyperglycaemia.

**Main results**
Analysis was by intention to treat. Fewer patients who received dexamethasone had an unfavourable outcome than did patients who received placebo (table). Also, fewer patients in the dexamethasone group died than in the placebo group (table). The groups did not differ for any other secondary outcomes. Dexamethasone and placebo groups did not differ for adverse effects.

**Conclusion**
In patients with acute bacterial meningitis, adjunctive treatment with dexamethasone was more effective than placebo in improving disability and reducing death.

*See glossary.
†Information provided by author.

**COMMENTARY**
Before the study of de Gans and van de Beek, only 3 randomised trials evaluated dexamethasone in adults with bacterial meningitis. The first, done in Egypt, showed a survival benefit in a subset of adults with pneumococcal meningitis. However, 60% of the patients were comatose at entry, and antibiotics were administered intramuscularly. The second study, which showed a trend to better outcomes with dexamethasone, enrolled only 60 patients of a planned 256, and dexamethasone could be administered up to 3 hours after the first dose of antibiotics. The third study, done in India, enrolled only 30 patients, and dexamethasone was started after antibiotics.

The study by de Gans and van de Beek addresses the limitations of the previous studies. The sample size was 301, and dexamethasone was given before or at the same time as the first antibiotic dose. The benefit of dexamethasone was largely restricted to those with pneumococcal meningitis.

The study was done principally in the Netherlands, where strains of *S. pneumoniae* with reduced susceptibility to penicillin are rare. In centres where reduced susceptibility of *S. pneumoniae* to a third generation cephalosporin exists, it is common for vancomycin to be used with a third generation cephalosporin for empirical treatment of bacterial meningitis pending culture and susceptibility results. However, evidence from animal studies shows that dexamethasone reduces penetration of vancomycin into infected cerebrospinal fluid. Thus, there is concern that use of dexamethasone with vancomycin could compromise the efficacy of vancomycin in third generation cephalosporin resistant strains. However, the vast majority of cases of bacterial meningitis are not caused by *S. pneumoniae* with reduced susceptibility to third generation cephalosporins. Thus, even if adjunctive dexamethasone was deleterious in patients with meningitis caused by *S. pneumoniae* resistant to third generation cephalosporins (which has not been established), many more patients would benefit from dexamethasone. Dexamethasone should now be considered the standard of care, provided that it is initiated before or at the same time as antibiotics.

Stephen D Shafran, MD
University of Alberta, Edmonton, Alberta, Canada

Dexamethasone improved disability in acute bacterial meningitis

Evid Based Med 2003 8: 86
doi: 10.1136/ebm.8.3.86

Updated information and services can be found at:
http://ebm.bmj.com/content/8/3/86

These include:

References
This article cites 6 articles, 1 of which you can access for free at:
http://ebm.bmj.com/content/8/3/86#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Infection (neurology) (20)
- Meningitis (15)
- Clinical trials (epidemiology) (1596)
- Diabetes (365)
- Immunology (including allergy) (571)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/